Beginning a new drug discovery collaboration using Congruence’s globally recognized Revenir™ platform for the creation of small molecule modulatorsExpanded collaboration into Ono’s other priority ...
Villarreal-Barragan brings global experience delivering first-in-human and complex biomarker-driven oncology trials for ...
TURKU, FI / ACCESS Newswire / March 2, 2026 / Faron Pharmaceuticals Ltd (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, ...
Nutraceuticals Market Growth Study, Future Trends, Demands, and Top Players Data by Forecast to 2030
The global nutraceuticals market, valued at approximately USD 416 billion in 2026, is projected to grow at a CAGR of around 9 ...
Heritage Global Partners (“HGP”), a subsidiary of Heritage Global Inc. (NASDAQ: HGBL) and a worldwide leader in asset advisory and auction services, today announced the official opening of its new ...
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, ...
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, ...
Cure Rare Disease (CRD), a non-profit biotechnology organization, today announced a landmark partnership with the LGMD2L Foundation. This collaboration is backed by a generous commitment of $7.65 ...
Demonstrating the power of adaptive design, NGHS and TLD Group celebrate six years of leadership growth across the health system. NEW YORK CITY, NY / ACCESS Newswire / March 2, 2026 / The Leadership ...
Brilliance Candida 2 Agar and Spectra Candida Agar support earlier detection, faster outbreak response and more informed treatment decisions in healthcare settings*WALTHAM, Mass.--(BUSINESS ...
TORONTO, ON / ACCESS Newswire / March 2, 2026 / Justera Health Ltd. (CSE:VTAL)(OTC PINK:SCRSF) ("Justera" or the "Company") announces that it signed a definitive share and asset purchase agreement ...
FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results